# Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma

> **NCT04699461** · PHASE2 · TERMINATED · sponsor: **ADC Therapeutics S.A.** · enrollment: 6 (actual)

## Conditions studied

- Relapsed Follicular Lymphoma
- Refractory Follicular Lymphoma

## Interventions

- **DRUG:** Loncastuximab Tesirine
- **DRUG:** Idelalisib

## Key facts

- **NCT ID:** NCT04699461
- **Lead sponsor:** ADC Therapeutics S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-04
- **Primary completion:** 2022-11-25
- **Final completion:** 2022-11-25
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Administrative decision (not due to safety reason)
- **Last updated:** 2023-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04699461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04699461, "Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04699461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*